Cargando…
Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel
The first local spread of COVID-19 in Israel was detected in March 2020. Due to the diversity in clinical presentations of COVID-19, diagnosis by RT-PCR alone might miss patients with mild or no symptoms. Serology testing may better evaluate the actual magnitude of the spread of infection in the pop...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059683/ https://www.ncbi.nlm.nih.gov/pubmed/33884542 http://dx.doi.org/10.1007/s10654-021-00749-1 |
_version_ | 1783681224889335808 |
---|---|
author | Reicher, Shay Ratzon, Ronit Ben-Sahar, Shay Hermoni-Alon, Sharon Mossinson, David Shenhar, Yotam Friger, Michael Lustig, Yaniv Alroy-Preis, Sharon Anis, Emilia Sadetzki, Siegal Kaliner, Ehud |
author_facet | Reicher, Shay Ratzon, Ronit Ben-Sahar, Shay Hermoni-Alon, Sharon Mossinson, David Shenhar, Yotam Friger, Michael Lustig, Yaniv Alroy-Preis, Sharon Anis, Emilia Sadetzki, Siegal Kaliner, Ehud |
author_sort | Reicher, Shay |
collection | PubMed |
description | The first local spread of COVID-19 in Israel was detected in March 2020. Due to the diversity in clinical presentations of COVID-19, diagnosis by RT-PCR alone might miss patients with mild or no symptoms. Serology testing may better evaluate the actual magnitude of the spread of infection in the population. This is the first nationwide seroprevalence study conducted in Israel. It is one of the most widespread to be conducted thus far, and the largest per-country population size. The survey was conducted between June 28 and September 14, 2020 and included 54,357 patients who arrived at the Health Maintenance Organizations to undergo a blood test for any reason. A patient was considered seropositive after two consecutive positive results with two different kits (Abbott and DiaSorin).The overall seroprevalence was 3.8% (95%CI 3.7–4.0), males higher than females [4.9% (95%CI 4.6–5.2) vs. 3.1% (95%CI 2.9–3.3) respectively]. Adolescents had the highest prevalence [7.8% (95%CI 7.0–8.6)] compared to other age groups. Participants who had undergone RT-PCR testing had a tenfold higher risk to be seropositive. The prevalence-to-incidence ratio was 4.5–15.7. Serology testing is an important complimentary tool for assessing the actual magnitude of infection and thus essential for implementing policy measures to control the pandemic. A positive serology test result was recently accepted in Israel as being sufficient to define recovery, with possible far-reaching consequences, such as the deploying of employees to ensure the maintenance of a functional economy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10654-021-00749-1. |
format | Online Article Text |
id | pubmed-8059683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-80596832021-04-22 Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel Reicher, Shay Ratzon, Ronit Ben-Sahar, Shay Hermoni-Alon, Sharon Mossinson, David Shenhar, Yotam Friger, Michael Lustig, Yaniv Alroy-Preis, Sharon Anis, Emilia Sadetzki, Siegal Kaliner, Ehud Eur J Epidemiol Covid-19 The first local spread of COVID-19 in Israel was detected in March 2020. Due to the diversity in clinical presentations of COVID-19, diagnosis by RT-PCR alone might miss patients with mild or no symptoms. Serology testing may better evaluate the actual magnitude of the spread of infection in the population. This is the first nationwide seroprevalence study conducted in Israel. It is one of the most widespread to be conducted thus far, and the largest per-country population size. The survey was conducted between June 28 and September 14, 2020 and included 54,357 patients who arrived at the Health Maintenance Organizations to undergo a blood test for any reason. A patient was considered seropositive after two consecutive positive results with two different kits (Abbott and DiaSorin).The overall seroprevalence was 3.8% (95%CI 3.7–4.0), males higher than females [4.9% (95%CI 4.6–5.2) vs. 3.1% (95%CI 2.9–3.3) respectively]. Adolescents had the highest prevalence [7.8% (95%CI 7.0–8.6)] compared to other age groups. Participants who had undergone RT-PCR testing had a tenfold higher risk to be seropositive. The prevalence-to-incidence ratio was 4.5–15.7. Serology testing is an important complimentary tool for assessing the actual magnitude of infection and thus essential for implementing policy measures to control the pandemic. A positive serology test result was recently accepted in Israel as being sufficient to define recovery, with possible far-reaching consequences, such as the deploying of employees to ensure the maintenance of a functional economy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10654-021-00749-1. Springer Netherlands 2021-04-21 2021 /pmc/articles/PMC8059683/ /pubmed/33884542 http://dx.doi.org/10.1007/s10654-021-00749-1 Text en © Springer Nature B.V. 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Covid-19 Reicher, Shay Ratzon, Ronit Ben-Sahar, Shay Hermoni-Alon, Sharon Mossinson, David Shenhar, Yotam Friger, Michael Lustig, Yaniv Alroy-Preis, Sharon Anis, Emilia Sadetzki, Siegal Kaliner, Ehud Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel |
title | Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel |
title_full | Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel |
title_fullStr | Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel |
title_full_unstemmed | Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel |
title_short | Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel |
title_sort | nationwide seroprevalence of antibodies against sars-cov-2 in israel |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059683/ https://www.ncbi.nlm.nih.gov/pubmed/33884542 http://dx.doi.org/10.1007/s10654-021-00749-1 |
work_keys_str_mv | AT reichershay nationwideseroprevalenceofantibodiesagainstsarscov2inisrael AT ratzonronit nationwideseroprevalenceofantibodiesagainstsarscov2inisrael AT bensaharshay nationwideseroprevalenceofantibodiesagainstsarscov2inisrael AT hermonialonsharon nationwideseroprevalenceofantibodiesagainstsarscov2inisrael AT mossinsondavid nationwideseroprevalenceofantibodiesagainstsarscov2inisrael AT shenharyotam nationwideseroprevalenceofantibodiesagainstsarscov2inisrael AT frigermichael nationwideseroprevalenceofantibodiesagainstsarscov2inisrael AT lustigyaniv nationwideseroprevalenceofantibodiesagainstsarscov2inisrael AT alroypreissharon nationwideseroprevalenceofantibodiesagainstsarscov2inisrael AT anisemilia nationwideseroprevalenceofantibodiesagainstsarscov2inisrael AT sadetzkisiegal nationwideseroprevalenceofantibodiesagainstsarscov2inisrael AT kalinerehud nationwideseroprevalenceofantibodiesagainstsarscov2inisrael |